IIT-Bhubaneswar & ILS Partner With TechInvention For Roll Out Of TB Vaccine

In a significant advancement in the fight against tuberculosis (TB), the Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS) have joined forces with TechInvention Lifecare Limited. This collaboration aims to transfer and commercialize a next-generation TB vaccine targeting Mycobacterium tuberculosis through a quadripartite license agreement (QLA).

The Global Burden of Tuberculosis

According to the World Health Organization (WHO), TB remains one of the deadliest infectious diseases worldwide, claiming approximately 1.23 million lives in 2024 alone. Despite the availability of the Bacillus Calmette Guérin (BCG) vaccine, developed over a century ago, its effectiveness is limited. The BCG vaccine primarily protects infants and has proven largely ineffective in preventing pulmonary TB in adolescents and adults.

Innovative Vaccine Development

To address this pressing public health need, a next-generation HSP Subunit Vaccine has been developed through collaborative research led by Professor Ashis Biswas from IIT Bhubaneswar and Dr. Sunil Kumar Raghav from ILS Bhubaneswar. This innovative vaccine is designed to induce robust humoral and cellular immune responses, significantly enhancing the protective effectiveness of the existing BCG vaccine.

Key Features of the HSP Subunit Vaccine

Targeted Approach: The vaccine specifically targets Mycobacterium tuberculosis, the bacterium responsible for TB.
Enhanced Immune Response: It aims to improve both humoral (antibody-mediated) and cellular (T-cell mediated) immune responses.
Collaboration: The development is a result of joint efforts between two premier research institutions in India, showcasing the country’s commitment to combatting TB.

Partnership with TechInvention Lifecare Limited

Under the terms of the quadripartite license agreement, TechInvention Lifecare Limited will take the lead in advancing the indigenous technology and translating it into a viable public health solution. The company is expected to complete Phase I and II clinical trials within the next four to five years, utilizing its expertise in vaccine development, regulatory compliance, and global health solutions.

Goals of the Collaboration

The partnership aims to ensure that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialization. This initiative is crucial for strengthening India’s mission to eliminate tuberculosis and highlights the transformative potential of indigenous, research-driven healthcare innovations for both national and global health.

Statements from Key Officials

Debasis Dash, the Director of ILS, emphasized the importance of this collaboration, stating, “This partnership ensures that the jointly developed vaccine candidate advances efficiently from research to product development, validation, and eventual commercialization. It strengthens India’s mission to eliminate tuberculosis and underscores the transformative potential of indigenous, research-driven healthcare innovations for national and global health.”

The Future of TB Vaccination

The development of the HSP Subunit Vaccine represents a significant advancement in India’s efforts to combat TB. With the ongoing global health challenges posed by infectious diseases, the timely rollout of this vaccine could play a pivotal role in reducing TB incidence and mortality rates.

Next Steps in Vaccine Development

The upcoming phases of clinical trials will be critical in determining the safety and efficacy of the HSP Subunit Vaccine. These trials will involve:

Phase I Trials: Focused on assessing the safety and immune response in a small group of healthy volunteers.
Phase II Trials: Aimed at evaluating the vaccine’s efficacy and further assessing its safety in a larger group.

Successful completion of these trials will pave the way for regulatory approval and eventual public distribution, marking a significant milestone in TB prevention strategies.

Conclusion

The partnership between IIT Bhubaneswar, ILS, and TechInvention Lifecare Limited is a promising development in the fight against tuberculosis. By leveraging innovative research and technology transfer, this collaboration aims to bring forth a next-generation vaccine that could significantly improve TB prevention efforts. As the world continues to grapple with infectious diseases, such initiatives are vital for enhancing public health outcomes.

Note: This article is based on current information and developments regarding the TB vaccine initiative as of November 2025.

Article Source

Disclaimer: IIT Buzz provides news and information for general awareness purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of any content. Opinions expressed are those of the authors and not necessarily of IIT Buzz. We are not liable for any actions taken based on the information published. Content may be updated or changed without prior notice.